Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024

Core Insights - Innovent Biologics reported positive results from the Phase 3 study of mazdutide, a dual agonist targeting GLP-1R and GCGR, showing significant reductions in liver fat content in overweight or obese Chinese adults [1][2][3] Company Overview - Innovent Biologics is a biopharmaceutical company focused on developing high-quality medicines for various diseases, including oncology, autoimmune, cardiovascular, and metabolic disorders [1][9] - The company has launched 10 products and has multiple assets in clinical trials, including five Phase 3 studies for mazdutide [9] Study Details - The GLORY-1 trial involved 610 Chinese adults with a BMI of ≥28 kg/m² or ≥24 kg/m² with at least one weight-related comorbidity, randomized to receive mazdutide or placebo for 48 weeks [2][3] - The study demonstrated that mazdutide treatment led to a mean relative reduction in liver fat content of −63.3% for the 4 mg dose and −73.2% for the 6 mg dose, compared to an 8.2% increase in the placebo group [3][4] Clinical Implications - The results indicate that mazdutide may be more effective than GLP-1 receptor mono-agonists and other dual-target agonists in reducing liver fat, addressing significant unmet clinical needs in metabolic dysfunction-associated fatty liver disease (MAFLD) [2][4] - A high percentage of participants treated with mazdutide achieved significant reductions in liver fat, with 95.5% achieving a ≥30% relative reduction and 77.3% normalizing liver fat levels [4] Market Context - Obesity is a leading risk factor for various chronic diseases, and the prevalence of obesity in China has reached alarming levels, necessitating effective pharmacological interventions [6] - Traditional obesity treatments in China have shown limited efficacy, highlighting the need for innovative solutions like mazdutide [6] Future Prospects - The promising results from the GLORY-1 study support further exploration of mazdutide's clinical value in treating MAFLD and metabolic disorders [5][7] - The first New Drug Application (NDA) for mazdutide was accepted by the CDE of China's NMPA for chronic weight management, indicating potential market entry [8]